VERA is trading at $40.86 (4.9% down) as investors take profits following a sharp rally sparked by the FDA’s accelerated approval of its IgA nephropathy drug, atacicept (Trutakna).
- The stock surged more than 8% on July 7, 2026, driven by the regulatory milestone and subsequent bullish price target hikes from analysts.
- Today’s pullback is characterized as a normal consolidation move occurring amid broader weakness in the overall market.